Zomedica’s QQ3 2026 quarter reflects a modest top-line recovery against a backdrop of ongoing operating losses. Revenue of $8.095 million rose 15.69% year over year and 16.24% quarter over quarter, while gross profit reached $5.436 million, producing a robust gross margin of 67.15%. This favorable gross margin underscores product mix strength and the pricing dynamics of the TRUFORMA platform, the company’s point-of-care diagnostic solution for companion animals. However, the company posted a substantial operating loss of $6.606 million and a net loss of $6.121 million, with EBITDA of approximately −$4.24 million and a negative net income margin of roughly −75.6%. The quarter featured meaningful fixed cost absorption as Zomedica continues to invest behind TRUFORMA adoption and PulseVet commercialization, contributing to elevated selling, general, and administrative expenses (SG&A) and R&D outlays.
On the balance sheet, liquidity remains robust. Cash and cash equivalents plus short-term investments totaled about $53.12 million, with cash at period-end of $7.50 million and a net debt position of roughly −$6.79 million (i.e., net cash). There is no long-term debt reported, providing a solid liquidity runway to fund ongoing product development and commercialization efforts. The company’s trailing four-quarter revenue approximates $29.45 million, suggesting a modest top-line trajectory that could improve if TRUFORMA adoption accelerates. The near-term investment thesis hinges on the sustainable monetization of TRUFORMA, continued operational discipline, and progress toward profitability as the top line benefits from broader market uptake.
Overall, Zomedica appears to be balancing a fragile profitability path with a meaningful cash cushion and strategic product initiatives. Investors should monitor TRUFORMA revenue contribution, expense control, and any progression toward positive EBITDA as catalysts for a potential re-rating.